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Abstract
Purpose: Synchronous primary endometrial and ovarian cancers are infrequent. The objective of this study is to 
evaluate clinicopathological characteristics of synchronous endometrial and ovarian cancers treated in our institution.
Materials and Methods: The clinicopathological characteristics of 12 patients with synchronous ovarian and endometrial 
cancers treated at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, from July 2005 to 
July 2015, were reviewed retrospectively in depth from hospital database. The WHO committee classification was used for 
the histologic determination and staged based on International Federation of Gynaecology and Obstetrics (FIGO) staging.
Results: The median age at the time of diagnosis was 50 years (range 23–66 years). The incidence of synchronous 
primary endometrial and ovarian cancers was 2.01% in patients with endometrial cancer. A total of seven patients were 
menopausal (58%) and eight patients were nulliparous (66%); the median body mass index (BMI) was 29 kg/m2 (range, 
20–38). Abnormal uterine bleeding was the most common presenting symptom. According to FIGO stage, 10 cases of 
endometrial were Stage I/II (84%) and two cases were Stage III (16%). Of the ovarian cancers, nine cases were Stage I/II 
(83.3%) and two cases were Stage III (16.7%). Endometrial cancer was the main pathological type in uterine carcinoma 
(86%) followed by serous carcinoma (14%), and similarly, for ovarian cancer, endometrial was the most common 
pathology (67%) followed by serous/clear cell (16%) and mucinous (16.7%). Most endometrial and ovarian primaries 
in our series were Grade I and II tumours, 83% and 66%, respectively. 8 patients (66%) had similar histology in both 
primaries. All patients underwent surgical intervention. Only one patient did not receive any post-operative adjuvant 
therapy. 10 patients received platinum-based adjuvant chemotherapy and six patients received adjuvant radiotherapy.
Conclusion: Synchronous primary endometrial and ovarian cancers are infrequent and distinct set of patients. 
Abnormal per vaginal bleed was the most common symptom which helped in early detection. Majority of the patients 
belong to concordant endometrial histology, low grade, had younger age and high BMI. Treatment should be tailored 
to the stage, histology and grade of the individual tumours.
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Introduction
Synchronous primary tumours of the endometrium and 
ovary are relatively uncommon, representing the most 
common combination of synchronous primary cancer 
of the female genital tract.[1-3] Approximately 5% of all 
patients with endometrial cancer appear to have ovarian 
cancer synchronously and 10% other way around.[4]
The pathogenesis remains unclear. According to the theory 
of a secondary Mullerian system, epithelium of cervix, 
uterus, fallopian tubes, ovaries and peritoneal surface has 
shared molecular receptors responding to carcinogenic 
stimulus, leading to the development of multiple primary 
malignancies synchronously.[5,6] However, no absolute 
specific criteria exist to determine whether they represent 
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metastasis, independent primary tumours or dysplastic 
process involving the Mullerian epithelium.
Patients with synchronous primary endometrial and ovarian 
cancers have distinct clinical characteristics including 
young age, obesity, premenopausal status and nulliparity.[7] 
The aim of the present retrospective study is to evaluate 
the clinicopathological characteristics of synchronous 
endometrial and ovarian cancer treated in our institution.
Materials and Methods
From July 2005 to July 2015, the hospital tumour registry 
and information systems identified 12 patients with 
synchronous ovarian and endometrial cancer. Electronic 
and archived medical records were accessed to obtain 
clinicopathological data including age at diagnosis, 
presenting symptoms, body mass index (BMI), parity, 
treatment, histological subtypes and stage of disease.
Of these 12 patients, eight patients presented with per 
vaginal bleeding and were diagnosed with primary uterine 
carcinoma on endometrial curetting. These patients 
underwent upfront total hysterectomy and bilateral salpingo-
oophorectomy, whereas four patients underwent upfront 
total hysterectomy, bilateral salpingo-oophorectomy, pelvic 
lymphadenectomy, omentectomy and peritoneal washings 
for suspected ovarian primary. The surgical specimens 
were reviewed by our pathologists and the diagnosis of 
synchronous malignancies was made according to the 
criteria by Scully et al.[8] All patients had incidental finding 
of synchronous second primary on surgical specimens.
Adjuvant therapy was proposed for selected patients 
based on an evaluation of the risk factors for the two 
synchronous carcinomas such as stage, grade, histology 
and accuracy of surgical staging.
Patients were considered at low risk, if they had endometrial 
cancer Stage IA Grade 1–2 and/or ovarian cancer Stage IA–B 
Grade 1; at intermediate risk, if they had endometrial cancer 
Stage IA Grade 3 and Stage IB Grade 1–2, and/or ovarian 
cancer Stage IA–B Grade 2 and at high risk, if they had 
endometrial cancer Stage IB Grade 3, Stage IIB and clear 
cell or serous carcinoma, and/or ovarian cancer Stage IC or 
any Grade 3. The risk of Stage IIA endometrial cancers was 
defined according to grade and depth of myometrium invasion.
Adjuvant chemotherapy was given to patients with 
intermediate and high-risk ovarian cancer.
Whereas adjuvant vaginal brachytherapy was given to 
intermediate or high-risk Stage I endometrial carcinomas, 
external beam radiotherapy along with vaginal brachytherapy 
was given to Stage II endometrial carcinoma.
Follow-up examinations were conducted every 3–4 months 
during the first 2 years, every 6 months during next 3 years 
and then once a year.
Results
The median age of the 12 patients was 50 years (range 
23–66 years). Four of the patients were aged <50, 
whereas eight patients were aged >50. The median BMI 
was 29 kg/m2 (range 20–38), 8 (67%) of the 12 patients 
were obese (BMI >28). A total of seven patients were 
menopausal (58%) and eight patients were nulliparous 
(66%). The most common presenting symptom was 
abnormal uterine bleeding occurring in 6 patients (50%), 
abdominal pain and abdominal fullness in 5 patients (42%) 
and only one case exhibited vaginal discharge [Table 1].
Of the 12 patients, eight had hysterectomy and bilateral 
salpingo-oophorectomy and the remaining four patients 
had total hysterectomy, bilateral salpingo-oophorectomy, 
omentectomy with appendectomy and pelvic lymph node 
dissection.
The histopathological characteristics of the endometrial 
cancers are listed in Table 2. We found that 50% of patient 
had Grade I tumours and 42% had International Federation 
of Gynaecology and Obstetrics (FIGO) Stage I cancers. 
Myometrium invasion was seen in 50% of patients and 
lymphovascular space invasion was not found in any patient.
The histopathological characteristics of the ovarian cancer are 
listed in Table 3. We found that 42% had FIGO Stage I cancers 
and 50% had Grade I cancers. Endometrial cancer was the 
main pathological type in uterine carcinoma (86%) followed 
by serous carcinoma (14%), and similarly, for ovarian cancer, 
endometrial was the most common pathology (67%) followed 
by serous/clear cell (16%) and mucinous (16.7%).
Concordant endometrial/endometrial histology was seen 
in 68% (8/12), endometrial/mucinous in 16% (2/12), 
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endometrial/serous in 8% (1/12) and endometrial/
mucinous in 8% (1/12) of patients.
A total of 10 patients received platinum-based adjuvant 
chemotherapy, five patients received both chemotherapy 
and radiotherapy and one patient received radiotherapy 
alone.
Discussion
The results of our study reflect the interesting data about 
the biological behaviour of synchronous endometrial and 
ovarian carcinomas. Reported incidence rates in literature 
range from 2% to 10%;[7-12] however it is 2.01% of all 
early-stage endometrial cancers treated at our institution.
The median age at diagnosis was 50 years. The previous 
studies have also reported a younger median age in patients 
with synchronous endometrial and ovarian cancers. It is 
worth mentioning, 3 women (25%) were under 40 years of 
age at the time of diagnosis. These data support previous 
reports about the development risk of coexisting cancer 
and the common presentation of synchronous cancer in 
premenopausal or women of reproductive age.[2,13,14]
Obesity is well-known risk factor for the development 
of endometrial cancer. Soliman et al. reported that 35% 
of patients were obese with BMI >30.[7] In the study by 
Nishimura et al., the mean BMI of Japanese females with 
synchronous primary endometrial and ovarian cancers 
was 22.6 ± 3.4 kg/m², but the authors did not report the 
obesity rates.[15] In the present study, the median BMI was 
29 kg/m2 (range 20–38), 8 (67%) of the 12 patients were 
obese (BMI >28).
The most common histology of synchronous ovarian 
and endometrial tumour is endometrial type.[7,13,16] In 
the present study, 86% of endometrial cancers and 67% 
of ovarian cancers were endometrial. We experienced 
that only 17% of endometrial and 25% of ovarian were 
poorly differentiated which was concordant with a 30% 
incidence typically detected in Stage I ovarian cancer. The 
incidence of myometrium invasion was 50% and there 
was no incidence of vascular invasion.
According to literature, most patients with synchronous 
cancers present with symptoms characteristic of 
endometrial cancer. Abnormal uterine bleeding and 
abdominal pain were the main presenting symptoms.
In our series, median follow-up was 9 months (range: 
4–41 months). Three patients experienced relapse. Other 
Table 1: Patient characteristics
Patient characteristics Number (%) 
Age 
<50 4 (23) 
>50 8 (67) 
Pre‑menopausal 6 (50) 
Postmenopausal 6 (50) 
Comorbid conditions 
Diabetes 3 (25) 
Hypertension 4 (33) 
Presenting symptoms 
Abnormal bleeding 6 (50) 
Abdominal/pelvic mass 0 
Abdominal distension 3 (25) 
Abdominal/pelvic pain 2 (17) 
Others 1 (8) 
Table 2: Tumour characteristics endometrial cancer
Characteristics Frequency number (%) 
Stage 
IA 5 (42) 
IB 4 (33) 
II 2 (17) 
III 1 (8) 
Myometrium invasion 
<50% 6 (50) 
>50% 6 (50) 
Grade 
I 6 (50) 
II 4 (33) 
III 2 (17) 
Histology 
Endometrial 10 (86) 
Serous 2 (14) 
Adjuvant radiotherapy 
Vaginal brachytherapy 5 (42) 
External pelvic and vaginal 
brachytherapy 
1 (8) 
None 6 (50) 
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patients are alive without relapse. Given the small number 
of patients, no overall or disease-free survival data could 
be ascertained.
Our study was conducted in a single institution rather 
than multicentre analysis. The major limitation of the 
study was limited number and retrospective review. The 
diagnosis of synchronous malignancy was confirmed only 
after pathologic examinations, and it was hard to predict 
before surgical staging.
Guidelines for adjuvant treatment in patients with 
synchronous cancers have not been yet established. It 
is not possible to make definitive conclusion on optimal 
treatment. The excellent outcome in low-stage, low-grade 
tumours treated with surgery alone, however, supports 
the merits of this approach. Patients with more advanced 
stage, unfavourable histologies and high-grade disease 
should receive treatment tailored to both tumours.
Conclusion
The incidence of synchronous endometrial and ovarian cancer 
is remarkable, especially in premenopausal or young woman 
of reproductive age. Synchronous carcinomas show very 
favourable pathological features compared with the general 
endometrial or ovarian cancers. Treatment should be tailored 
to the histology, stage and grade of the individual tumours.
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Table 3: Tumour characteristics ovarian cancer
Characteristics Frequency number (%) 
Stage 
IA 5 (42) 
IB 3 (25) 
IC 2 (17) 
IIIA 2 (16) 
Grade 
I 6 (50) 
II 2 (17) 
III 3 (25) 
Unknown 1 (8) 
Histology 
Endometrial 8 (67) 
Clear 1 (8) 
Serous 1 (8) 
Mucinous 2 (17) 
Adjuvant chemotherapy 
Yes 10 (84) 
No 2 (16) 
